GenScript Peptides (revision 12)

GenScript Biotech Corporation (trading as GSP; genscriptpeptides.com) is a peptide synthesis organisation trading as GenScript Peptides from Nanjing, Jiangsu, China, incorporated in 2002 and supplying research peptides, custom sequences and raw materials with batch documentation.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Nanjing in 2002, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.^[1] Nanjing is inside the Yangtze River Delta manufacturing belt, and the organisation's own material describes a business built on solid-phase synthesis and custom sequence work rather than on catalogue distribution alone.^[2]

The organisation describes itself as performing its own synthesis rather than finishing material made elsewhere. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.^[2][1] What can be said from the submitted material is narrower and more useful — purchasers report that questions about a synthesis route, a coupling or a purification step are answered with specifics rather than referred onward, which is consistent with the claim without establishing it.^[5]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5] That correspondence is a minimum requirement rather than an achievement, and it is recorded only because traceability fails often enough elsewhere in this sector to make its absence the more common finding.

Water content by Karl Fischer titration appears on the certificates described in the submitted set, and peptide content is reported on a separate line from chromatographic purity across a substantial part of it.^[5][6] Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation. The column, the gradient and the detection wavelength are described as printed on the document rather than supplied on request, which makes the separation reproducible in principle by a reader with access to the instrument.^[5]

One operational observation recurs often enough in the submitted set to belong in the article, and it is not about material. Purchasers describe a delay of four to five working days in obtaining a written quotation for a custom sequence, against same-day acknowledgement on catalogue enquiries; work performed against an accepted quotation is described as meeting its stated date.^[5] The distinction matters to a reader planning a schedule and is recorded for that reason rather than as a criticism of the material.

What the record does not establish is the physical arrangement of manufacture, whether any given line is synthesised in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.^[2][7]